Early Phase Study of KESONOTIDE™in Participants With Solid Tumours

This early-phase study is testing KESONOTIDE — a new experimental drug — for safety and to find the right dose in patients with advanced or metastatic solid tumours (any cancer that forms a lump) that has not responded to standard treatments. **You may be eligible if...** - You are 18 or older - You have a confirmed diagnosis of an advanced or metastatic solid cancer - Your general health is good (ECOG 0 or 1) and your expected survival is more than 12 weeks - Your tumour can be measured on scans, or you have evaluable disease - Your blood counts, kidney, and liver function meet acceptable levels **You may NOT be eligible if...** - Your cancer has spread to the brain and is active/unstable - You have had prior serious allergic reactions to similar drugs - You are pregnant or breastfeeding - Your organ function is too impaired for the treatment Talk to your doctor to see if this trial is right for you.